Anji Pharma Revenue and Competitors

Location

$105M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Anji Pharma's estimated annual revenue is currently $1.1M per year.(i)
  • Anji Pharma's estimated revenue per employee is $100,500
  • Anji Pharma's total funding is $105M.

Employee Data

  • Anji Pharma has 11 Employees.(i)
  • Anji Pharma grew their employee count by -48% last year.

Anji Pharma's People

NameTitleEmail/Phone
1
Head BiologicsReveal Email/Phone
2
Head ResearchReveal Email/Phone
3
General CounselReveal Email/Phone
4
Head Regulatory AffairsReveal Email/Phone
5
Head Clinical OperationsReveal Email/Phone
6
Head CMCReveal Email/Phone
7
Clinical Operations DirectorReveal Email/Phone
8
Chief People OfficerReveal Email/Phone
9
Director, Global Strategic Operations and Alliance ManagementReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Anji Pharma?

Anji Pharma is a global pharmaceutical company focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

keywords:N/A

$105M

Total Funding

11

Number of Employees

$1.1M

Revenue (est)

-48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Anji Pharma News

2022-03-22 - Peptide Therapeutics: Contract API Manufacturing Market ...

As pharma companies resume full-scale operation after the COVID-19 outbreak, ... AnGes; Anji Pharmaceuticals; Antagene; APAC Pharmaceutical...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M11N/AN/A
#2
$1.8M11N/AN/A
#3
$3.5M11-31%$116.2M
#4
$2.9M110%N/A
#5
$0.9M11-45%$107M